Interview: Novartis's Big Hopes For Beovu
Drug Gets EU Okay For Wet AMD
After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.
You may also be interested in...
Novartis Hopes Eye Drug Beovu Bounces Back After New Approval
Having struggled to allay safety concerns for its use in wet age-related macular degeneration, the Swiss major has faith Beovu's efficacy and less frequent dosing will prove more than a match for established DME rival Eylea and newcomer Vabysmo.
Blow For Novartis Eye Drug Beovu As Studies Stop On Safety Worries
The Swiss giant Novartis has decided to halt the MERLIN, RAVEN and RAPTOR studies of Beovu "in the interests of patient safety" which will make the task of competing with the wet AMD market leader Eylea even tougher.
Will Beovu Be A Slow-Burning Blockbuster?
Expanded indications will be key for Novartis's Beovu and a successful diabetic macular edema trial has provided a fillip, a week after the wet AMD-approved drug posted a 44% slump in sales.